Dyne Therapeutics (DYN) Set to Announce Earnings on Wednesday

Key Points

• Dyne Therapeutics is expected to report Q3 2026 results after market close on November 4. Analysts forecast a quarterly loss of $0.9123 per share, compared with a $1.08-per-share loss reported in the prior quarter.
• The stock opened at $16.94, near the lower end of its 52-week range of $14.00 to $27.31. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $31.29, although Oppenheimer recently downgraded the shares and cut its target to $15.
• Insider activity has been mixed: Director Brian S. Posner bought 2,500 shares, while Director Jason P. Rhodes sold more than 2.16 million shares under a Rule 10b5-1 plan. Dyne is a clinical-stage biotechnology company developing genetic medicines for muscle diseases, including myotonic dystrophy and Duchenne muscular dystrophy.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.9123) per share for the quarter. Parties can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 3:00 PM ET.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts expect Dyne Therapeutics to post ($3.59) EPS for the current fiscal year and ($3.27) EPS for the next fiscal year.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $16.94 on Wednesday. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of -5.09 and a beta of 1.12. The stock has a 50 day moving average price of $19.09 and a 200-day moving average price of $19.32. Dyne Therapeutics has a one year low of $14.00 and a one year high of $27.31.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DYN. Oppenheimer downgraded Dyne Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $40.00 to $15.00 in a research report on Wednesday. Robert W. Baird dropped their price objective on shares of Dyne Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Wednesday, September 9th. Stifel Nicolaus set a $37.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. Cantor Fitzgerald reissued a "buy" rating on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Finally, Morgan Stanley lowered their target price on shares of Dyne Therapeutics from $45.00 to $36.00 and set an "overweight" rating for the company in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.29.

Insiders Place Their Bets

In related news, Director Brian S. Posner acquired 2,500 shares of the stock in a transaction on Friday, October 2nd. The stock was bought at an average cost of $16.00 per share, with a total value of $40,000.00. Following the transaction, the director directly owned 27,000 shares in the company, valued at approximately $432,000. This represents a 10.20% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares in the company, valued at $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,598,706 shares of company stock valued at $65,432,671 in the last three months. 9.46% of the stock is owned by company insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company's research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne's pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.